CN Patent
CN111358795A — 一种枸橼酸托法替布制剂及其制备方法
Assigned to Zhejiang Wansheng Pharmaceutical Co ltd · Expires 2020-07-03 · 6y expired
What this patent protects
本发明涉及一种新的枸橼酸托法替布制剂及其制备方法。该枸橼酸托法替布制剂有良好的吸收和生物利用度。该制剂采用干法制粒,工艺简单,原料不需要微粉化,减少原料损失,不引入多余水分,保证后续生产、运输和储存中稳定,延长货架期。
USPTO Abstract
本发明涉及一种新的枸橼酸托法替布制剂及其制备方法。该枸橼酸托法替布制剂有良好的吸收和生物利用度。该制剂采用干法制粒,工艺简单,原料不需要微粉化,减少原料损失,不引入多余水分,保证后续生产、运输和储存中稳定,延长货架期。
Drugs covered by this patent
- Xeljanz (Tofacitinib Citrate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.